Sign In
29 Oct 2012 12:01
For immediate release | 29 October 2012 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, has today been notified of the following transactions under the Abcam plc Share Incentive Plan to the benefit of the Executive Directors and PDMRs in line with the regular annual invitation to participate:
Name | Partnership Shares purchased on 26 October 2012 at 381p per 0.2 pence Ordinary Share | Matching Shares granted on 26 October 2012 at 381p per 0.2 pence Ordinary Share | Free Shares awarded on 26 October 2012 at 381p per 0.2 pence Ordinary Share | |
Executive Directors: | Jonathan Milner | 393 | 393 | 787 |
Jim Warwick | 393 | 393 | 787 | |
Jeff Iliffe | 393 | 393 | 787 | |
PDMRs: | Mark Bushfield | 394 | 394 | 787 |
Jane Cooke | 394 | 394 | 787 | |
Philippe Cotrel | 394 | 394 | 787 | |
Ed Ralph | 393 | 393 | 787 |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded. The risk of forfeiture attached to the Free Shares will normally be removed on the third anniversary of the award subject to continued employment.
No consideration was paid by the above grantees for the award of the Matching and Free Shares and no consideration is due on the release of these shares.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.
Abcam now has an online catalogue of over 98,500 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science reagents company.
Follow the stocks
